Surgical Innovation for Diabetes Treatment 2 (SURIDIAB2)

Characterization of Intestinal Hormone and Glucose Dynamics to Unravel the Antidiabetic Effect of Bariatric Surgery

This study aims to understand the enteroendocrine physiological changes in superobese patients submitted to two different bariatric procedures (biliopancreatic diversion with duodenal switch versus single anastomosis duodeno-ileal bypass), when perfomed as primary or revisional surgeries (after a sleeve gastrectomy). The main purpose is to establish the metabolic changes obtained with the sleeve gastrectomy and how the revisional procedure maximizes those changes. Additionally, the study will determine whether BPD with DS or SADI-S is superior than the other as first choice for the superobese.

The study will monitor the enteroendocrine function before and after the ingestion of a mixed meal, in pre-operatory and post-surgery timepoints, comparing both primary and revisional surgeries.

Study Overview

• Status: Recruiting
• Conditions: Enteroendocrine Physiological Changes in Superobese Patients Submitted to Two Different Bariatric Procedures; Determine Whether BPD With DS or SADI-S as Primary or Revisional Surgery is Superior Than the Other as First Choice for the Superobese; Determine Whether or Not Revision Surgery is as Effective as Primary Surgery and Understand the Physiological Mechanisms Inherent in These Putative Differences
• Intervention / Treatment: Procedure: Single anastomosis duodeno-ileal bypass; Procedure: Biliopancreatic diversion with duodenal switch; Procedure: SADI-S as a revisional procedure; Procedure: BPD-DS as a revisional procedure

Detailed Description

Abstract Obesity is a chronic disease whose global incidence keeps rising as the twenty first century goes on. Nowadays, the surgical approach constitutes the best treatment option for these patients, making the sleeve gastrectomy and the gastric bypass the more frequently performed bariatric surgeries.

However, the superobese patients (IMC≥ 50kg/m2) present variable weight loss resistance to the previous techniques, showing better results when submitted to disabsorptive procedures, namely the biliopancreatic diversion with duodenal switch, and the more recently created single anastomosis duodeno-ileal bypass. Each constitutes a revisional surgery option after a primary sleeve gastrectomy, reducing surgical and anesthesia risks. This has brought to light that some superobese patients do not need the revisional procedure as they achieve the weight loss target solely by the vertical gastrectomy.

Supported on the investigators' previous work and extensive experience performing both techniques, they now aim to understand the enteroendocrine physiological changes which each procedure accomplishes and compare them in terms of therapeutic efficacy among the superobese. The utmost goals will be to unravel the advantages of BPD-DS and SADI-S as primary or revisional surgeries, the differences between patients that respond well to sleeve gastrectomy alone and those who do not, and, finally, providing further insights on which procedure should be favoured over the other based on the patient characteristics.

Study Overview:

Participants in this study will have been submitted to either BPD-DS or SADI-S, as a primary or as a revisional surgery.

• Participants visits will be scheduled before surgery and after surgery at 3, 6 , 12 and 24 months for those who receive BPD-DS or SADI-S as a primary procedure.
• Those who are firstly submitted to the sleeve gastrectomy, visits will be scheduled before surgery and after surgery at 3 , 6 and 12 months. The revisional surgery will take place 1 year after the sleeve, with visits scheduled before surgery and after surgery at 3, 6 and 12 months.

In all these visits, detailed participants assessment will include vitals, anthropometric and biochemical evaluation, and the performance of a MMTT with plasma sampling for hormonal profiles. Intraoperative sampling of visceral and subcutaneous adipose tissue will take place during BPD-DS or SADI-S as a primary procedure and during the sleeve gastrectomy and repeated 1 year after the revisional surgery, either BPD-DS or SADI-S, is performed.

Participant Enrolment:

Participants will be selected from the cohort of patients referred for multidisciplinary evaluation by the clinical team for surgical treatment of obesity of the Centro Hospitalar Entre Douro e Vouga (CHEDV). Participants found to be suitable according to the entry criteria and who have accepted to participate will be enrolled in the study and assigned to one of the four study groups according to participants clinical features.

• Study Type: Interventional
• Enrollment (Anticipated): 40
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Marta Guimarães, PhD; Phone Number: 5575 0034256379700; Email: marta.guimaraes@chedv.min-saude.pt
• Study Contact Backup: Name: Ana Marta Pereira, MD; Phone Number: 0034256379700; Email: amarta.pereira@chedv.min-saude.pt

Study Locations

• Portugal
  • Santa Maria Da Feira, Portugal
    • Recruiting
    • Hospital de Sao Sebastiao
    • Contact: Ana Marta Pereira, MD; Phone Number: 0034256379700; Email: amarta.pereira@chedv.min-saude.pt
    • Principal Investigator: Ana Marta Pereira, MD
    • Sub-Investigator: Mário Nora, MD
    • Contact: Marta Guimarães, PhD; Phone Number: 0034256379700; Email: marta.guimaraes@chedv.min-saude.pt
    • Sub-Investigator: Mariana P. Monteiro, PhD
  • Aveiro
    • Santa Maria Da Feira, Aveiro, Portugal, 4520-211
      • Recruiting
      • São Sebastião Hospital
      • Contact: Marta Guimarães, PhD, MD; Phone Number: 00351962347298; Email: marta.guimaraes@chedv.min-saude.pt
      • Contact: Ana Marta Pereira, MD; Phone Number: 00351962347298; Email: amarta.pereira@chedv.min-saude.pt
      • Principal Investigator: Ana Marta Pereira, MD
      • Sub-Investigator: Mário Nora, MD
      • Sub-Investigator: Mariana P. Monteiro, PhD, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

Bariatric surgery candidates

• BMI between 45 and 55 kg/m2
• Aged between 18 and 65 years at surgery

Exclusion Criteria:

• Previous abdominal surgery
• Diabetic patients (Hb A1c > 5,7%) prior to the bariatric procedure
• Treatment with antidiabetic drugs, except for purposes other than diabetes treatment, prior to the bariatric procedure

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: SADI-S as a primary surgery	Procedure: Single anastomosis duodeno-ileal bypass; Sleeve gastrectomy followed by division of the duodenum bypassing the jejunum with end-to-side duodeno-ileal diversion; Other Names: SADI-S
Active Comparator: BPD-DS as a primary surgery	Procedure: Biliopancreatic diversion with duodenal switch; Sleeve gastrectomy, followed by division of the duodenum bypassing the jejunum with end-to-side duedeno-ileal diversion and Roux-en-y entero-enteric anastomosis, leaving 100 cm common channel.; Other Names: BPD-DS
Active Comparator: SADI-S as a revisional procedure	Procedure: SADI-S as a revisional procedure; In patients previously submitted to sleeve gastrectomy a single anastomosis duodeno-ileal bypass will be performed as 2nd time surgery
Active Comparator: BPD-DS as a revisional procedure	Procedure: BPD-DS as a revisional procedure; In patients previously submitted to sleeve gastrectomy a biliopancreatic diversion with duodenal switch will be performed as 2nd time surgery

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in body mass index	Body mass index (BMI) combines height (in meters) and weight (in kilograms) and is calculated as weight over (height)^2. Therefore, it will be reported in kg/m^2. This parameter will be determined at each study timepoint (pre-operatory, 3, 6 and 12 months post-surgery) at presential visits to the clinic.	From enrolment to 12 months post-intervention in 4 visits: preoperative, 3, 6 and 12 months post-surgery
Change in glycated haemoglobin	Glycated haemoglobin (HbA1c) will be measured in percentage (%). This parameter will be assessed at each study timepoint (pre-operatory, 3, 6 and 12 months post- surgery) through routine complete biochemical evaluation.	From enrolment to 12 months post-intervention in 4 visits: preoperative, 3, 6 and 12 months
Change in glucose dynamic profile	Glucose will be measured in mmol/L. This parameter will be assessed at each study timepoint (pre-operatory, 3, 6 and 12 months post-surgery) under fasting conditions and during a mixed-meal tolerance teste (MMTT) with blood collection at eight timed intervals (-10, 0, 15, 30, 45, 60, 90 and 120 minutes).	From enrolment to 12 months post-intervention in 4 visits: preoperative, 3, 6 and 12 months
Change in insulin dynamic profile	Insulin will be measured in mIU/L. This parameter will be assessed at each study timepoint (pre-operatory, 3, 6 and 12 months post-surgery) under fasting conditions and during a mixed-meal tolerance teste (MMTT) with blood collection at eight timed intervals (-10, 0, 15, 30, 45, 60, 90 and 120 minutes).	From enrolment to 12 months post-intervention in 4 visits: preoperative, 3, 6 and 12 months post-surgery
Change in glucagon dynamic profile	Glucagon will be measured in pmol/L. This parameter will be assessed at each study timepoint (pre-operatory, 3, 6 and 12 months post-surgery) under fasting conditions and during a mixed-meal tolerance teste (MMTT) with blood collection at eight timed intervals (-10, 0, 15, 30, 45, 60, 90 and 120 minutes).	From enrolment to 12 months post-intervention in 4 visits: preoperative, 3, 6 and 12 months post-surgery
Change in GLP-1 dynamic profile	Glucagon-like peptide-1 (GLP-1) will be measured in pmol/L. This parameter will be assessed at each study timepoint (pre-operatory, 3, 6 and 12 months post-surgery) under fasting conditions and during a mixed-meal tolerance teste (MMTT) with blood collection at eight timed intervals (-10, 0, 15, 30, 45, 60, 90 and 120 minutes).	From enrolment to 12 months post-intervention in 4 visits: preoperative, 3, 6 and 12 months post-surgery
Change in GIP dynamic profile	Glucose-dependent insulinotropic polypeptide (GIP) will be measured in pmol/L. This parameter will be assessed at each study timepoint	From enrolment to 12 months post-intervention in 4 visits: preoperative, 3, 6 and 12 months post-surgery

Secondary Outcome Measures

Outcome Measure	Time Frame
Hypertension remission rates	From enrolment to 12 months post-intervention in 4 visits: preoperative, 3, 6 and 12 months post-surgery
Dyslipidemia remission rates	From enrolment to 12 months post-intervention in 4 visits: preoperative, 3, 6 and 12 months post-surgery
Sleep Apnea remission rates	From enrolment to 12 months post-intervention in 4 visits: preoperative, 3, 6 and 12 months post-surgery
Metabolic syndrome remission rates	From enrolment to 12 months post-intervention in 4 visits: preoperative, 3, 6 and 12 months post-surgery

Other Outcome Measures

Outcome Measure	Time Frame
Surgical morbidity	From surgery date to 3 months post-surgery
Surgical mortality	From surgery date to 3 months post-surgery
Late morbidity	From 3 months until 4 years post-surgery

Collaborators and Investigators

• Sponsor: Hospital de Sao Sebastiao
• Collaborators: Instituto de Ciências Biomédicas Abel Salazar; The Novo Nordisk Foundation Center for Basic Metabolic Research

Study record dates

Study Major Dates

• Study Start (Actual): August 16, 2020
• Primary Completion (Actual): August 16, 2022
• Study Completion (Anticipated): February 1, 2025

Study Registration Dates

• First Submitted: January 13, 2021
• First Submitted That Met QC Criteria: January 13, 2021
• First Posted (Actual): January 15, 2021

Study Record Updates

• Last Update Posted (Actual): August 17, 2022
• Last Update Submitted That Met QC Criteria: August 15, 2022
• Last Verified: August 1, 2022

More Information

Terms related to this study

• Keywords: Bariatric Surgery; Superobesity; Revisional Bariatric Surgery; Single anastomosis duodeno-ileal bypass; Biliopancreatic diversion with duodenal switch
• Other Study ID Numbers: HSS

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No